Rigel Pharmaceuticals Inc RIGL
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover RIGL, but with our powerful screener, you can find stocks in the same sector, industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
-
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
-
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
-
Rigel Pharmaceuticals Provides Business Update
-
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
-
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Trading Information
- Previous Close Price
- $1.49
- Day Range
- $1.46–1.51
- 52-Week Range
- $0.71–1.96
- Bid/Ask
- $1.48 / $1.65
- Market Cap
- $259.56 Mil
- Volume/Avg
- 782,389 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.20
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 147
- Website
- https://www.rigel.com
Comparables
Valuation
Metric
|
RIGL
|
ALVR
|
CHRS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.59 | — |
Price/Sales | 2.20 | — | 0.87 |
Price/Cash Flow | — | — | — |
Price/Earnings
RIGL
ALVR
CHRS
Financial Strength
Metric
|
RIGL
|
ALVR
|
CHRS
|
---|---|---|---|
Quick Ratio | 1.64 | 6.49 | 1.14 |
Current Ratio | 1.86 | 6.61 | 1.43 |
Interest Coverage | −2.98 | — | −4.88 |
Quick Ratio
RIGL
ALVR
CHRS
Profitability
Metric
|
RIGL
|
ALVR
|
CHRS
|
---|---|---|---|
Return on Assets (Normalized) | −13.18% | −52.75% | −27.74% |
Return on Equity (Normalized) | — | −66.34% | — |
Return on Invested Capital (Normalized) | −36.17% | −59.54% | −32.60% |
Return on Assets
RIGL
ALVR
CHRS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Whdzksjhr | Lltd | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xsqvdnmh | Tbdmrt | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pwlpytzfz | Shwcb | $105.6 Bil | |
MRNA
| Moderna Inc | Sznghkgbz | Vftsz | $40.8 Bil | |
ARGX
| argenx SE ADR | Qqdpnjbw | Dtr | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Pjdppkl | Rcz | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bsbvwfzrp | Mqgwdrf | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qfklwglw | Hgcvxqr | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wwxgzmyfm | Dgyjdb | $13.6 Bil | |
INCY
| Incyte Corp | Klhlpbc | Krggmz | $12.8 Bil |